03:18 , Aug 2, 2019 |  BC Innovations  |  Product Development

Boehringer plays catch-up in NASH, dives into new modalities across the board

Although Boehringer’s recent spate of deals plug pipeline holes in fibrosis and cancer, a broader survey of the pharma’s partnering activity over the last two years shows it delving into technologies that let it jump...
20:58 , Jul 18, 2019 |  BC Extra  |  Company News

Boehringer deal enables Bridge to expand pipeline, take in-house programs further

In the latest sign of success for Bridge's strategy to translate first-in-class compounds discovered in Asia, the Korean biotech granted Boehringer exclusive global rights to its lung fibrosis candidate BBT-877. The partnership is the second...
20:55 , Apr 1, 2019 |  BC Extra  |  Financial News

Bridge raises $27.2M series C led by UTC, Shinhan

Bridge has parlayed a partnership with Daewoong on the South Korean biotech’s lead ulcerative colitis asset into a W31 billion ($27.2 million) series C round, which was led by returning investor UTC Investment Co. and...
19:33 , Feb 1, 2019 |  BC Week In Review  |  Company News

Bridge Biotherapeutics gets rights to kinase inhibitor from Korea Research Institute

Korea Research Institute of Chemical Technology (Daejeon, South Korea) granted Bridge Biotherapeutics Inc. (Seongnam, South Korea) exclusive, worldwide rights to an undisclosed kinase inhibitor. Korea Research Institute will receive W30 billion ($26.6 million), which includes...
19:28 , Dec 21, 2018 |  BC Week In Review  |  Company News

Bridge, Daewoong partner on BBT-401 for ulcerative colitis

Bridge Biotherapeutics Inc. (Seongnam, South Korea) and Daewoong Pharmaceutical Co. Ltd. (KSE:069620) partnered to co-develop BBT-401 to treat ulcerative colitis. Bridge will receive an undisclosed upfront payment and be eligible for up to $40 million...
16:03 , Nov 16, 2018 |  BC Week In Review  |  Clinical News

Bridge's ulcerative colitis candidate headed for Phase II

Bridge Biotherapeutics Inc. (Seongnam, South Korea) said single and multiple ascending doses of oral ulcerative colitis candidate BBT-401 were well tolerated with minimal systemic exposure observed in a Phase I trial in 80 healthy volunteers....
16:45 , Sep 7, 2018 |  BC Week In Review  |  Clinical News

Bridge's BBT-877 reduces lung fibrosis in mouse model of IPF

Bridge Biotherapeutics Inc. (Seongnam, South Korea) said BBT-877 reduced lung fibrosis as measured by Ashcroft scores and deposition of collagen in a mouse model of bleomycin-induced idiopathic pulmonary fibrosis (IPF). Data were presented at the...
23:30 , May 1, 2018 |  BC Innovations  |  Distillery Therapeutics

Pulmonary

INDICATION: Pulmonary fibrosis In vitro and mouse studies identified a hydroxamic acid-based ENPP2 inhibitor that could help treat pulmonary fibrosis. Chemical synthesis and in vitro testing in enzymatic activity assays of hydroxamic acid analogs yielded...
05:19 , Jun 16, 2017 |  BC Week In Review  |  Company News

LegoChem grants Bridge Biotherapeutics rights to autotaxin candidate

Bridge Biotherapeutics Inc. (Seongnam, South Korea) said it received exclusive, worldwide rights to a small molecule inhibitor of autotaxin ( ENPP2 ; ATX) from LegoChem Biosciences Inc. (KOSDAQ:141080). LegoChem will receive KrW2 billion ($1.8 million)...
23:38 , Nov 21, 2016 |  BioCentury  |  Strategy

LG’s biotech legacy

LG Life Sciences Ltd. was a pioneer, producing the first globally approved drugs developed by a South Korean company. A shift in priorities all but stopped the flow of innovative new drugs to the world...